AbbVie (ABBV) has been in the limelight with various recent achievements impacting its market performance. Gaining whilst the market dips, AbbVie received FDA Approval for the MAVYRET Label Expansion to treat Pediatric Hepatitis C. This confirms AbbVie's MAVYRET as the first treatment for acute Hepatitis C Virus. The company also filed a Biologics License Application with the U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the treatment of Glabellar Lines.
ABBV participated in corporate social responsibility, partnering with the Chicago Cubs on 'Striking Out Cancer'. It also received attention for its various dividend growth stocks with high yields. Gaining FDA approval for its new cancer drug Emrelis provides hope for driving ABBV's oncology franchise. ABBV scored a major legal victory over a $63 billion Allergan Shareholder Lawsuit granting it further credibility.
Down about 13% in three months, the current 'dip' in AbbVie's stock amidst marked achievements and innovative developments could make the stock a desirable acquisition for investors eyeing long-term growth.
Abbvie ABBV News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Fri, 13 Jun 2025 20:22:01 GMT - Rating 5 - Innovation 6 - Information 9 - Rumor 0
